{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:40:11Z","timestamp":1790872811403,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.transproceed.2021.04.011","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T11:54:59Z","timestamp":1621338899000},"page":"1589-1598","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Risk Factors and Management of Leukopenia After Kidney Transplantation: A Single-Center Experience"],"prefix":"10.1016","volume":"53","author":[{"given":"Max","family":"Henningsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Jaenigen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Zschiedrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Przemyslaw","family":"Pisarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Walz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2021.04.011_bib0001","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/j.1399-0012.2008.00893.x","article-title":"Management of leukopenia in kidney and pancreas transplant recipients","volume":"22","author":"Hartmann","year":"2008","journal-title":"Clin Transplant"},{"issue":"3B Suppl","key":"10.1016\/j.transproceed.2021.04.011_bib0002","doi-asserted-by":"crossref","first-page":"16S","DOI":"10.1016\/S0041-1345(99)00096-2","article-title":"Leukocyte response to thymoglobulin or atgam for induction immunosuppression in a randomized, double-blind clinical trial in renal transplant recipients","volume":"31","author":"Brennan","year":"1999","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2021.04.011_bib0003","first-page":"1135","article-title":"A retrospective comparison of the efficacy and safety in kidney transplant recipients with basiliximab and anti-thymocyte globulin","volume":"125","author":"Wang","year":"2012","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.transproceed.2021.04.011_bib0004","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000473941","article-title":"Frequency of leukopenia incidents following azathioprine therapy after kidney transplantation","volume":"4","author":"Oesterwitz","year":"1978","journal-title":"Eur Urol"},{"key":"10.1016\/j.transproceed.2021.04.011_bib0005","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3389\/fcell.2015.00018","article-title":"Blood disorders typically associated with renal transplantation","volume":"3","author":"Yang","year":"2015","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.transproceed.2021.04.011_bib0006","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/S0140-6736(77)92683-6","article-title":"Allopurinol and agranulocytosis","volume":"2","author":"Wilkinson","year":"1977","journal-title":"Lancet"},{"key":"10.1016\/j.transproceed.2021.04.011_bib0007","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/art.1780150413","article-title":"Aplastic agranulocytosis after allopurinol therapy","volume":"15","author":"Greenberg","year":"1972","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.transproceed.2021.04.011_bib0008","first-page":"286","article-title":"Reversible flu-like syndrome, leukopenia, and thrombocytopenia induced by allopurinol","volume":"15","author":"Rosenbloom","year":"1981","journal-title":"Drug Intell Clin Pharm"},{"key":"10.1016\/j.transproceed.2021.04.011_bib0009","series-title":"Treasure Island","article-title":"Allopurinol","author":"Qurie","year":"2021"},{"key":"10.1016\/j.transproceed.2021.04.011_bib0010","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1440-1746.2010.06254.x","article-title":"Azathioprine and allopurinol: a two-edged interaction","volume":"25","author":"Gearry","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.transproceed.2021.04.011_bib0011","doi-asserted-by":"crossref","first-page":"690","DOI":"10.2215\/CJN.07320810","article-title":"Tacrolimus-induced neutropenia in renal transplant recipients","volume":"6","author":"De Rycke","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.transproceed.2021.04.011_bib0012","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1097\/00007890-200005270-00019","article-title":"Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management","volume":"69","author":"Hong","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2021.04.011_bib0013","doi-asserted-by":"crossref","first-page":"560","DOI":"10.7326\/0003-4819-93-4-560","article-title":"Neutropenia and thrombocytopenia in renal allograft recipients treated with trimethoprim-sulfamethoxazole","volume":"93","author":"Bradley","year":"1980","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.transproceed.2021.04.011_bib0014","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1111\/j.1600-6143.2011.03611.x","article-title":"Impact of cytomegalovirus disease in D+\/R\u2212 kidney transplant patients receiving 6 months low-dose valganciclovir prophylaxis","volume":"11","author":"Luan","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2021.04.011_bib0015","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1681\/ASN.2004121113","article-title":"Viral infection in the renal transplant recipient","volume":"16","author":"Kotton","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.transproceed.2021.04.011_bib0016","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/TP.0b013e31821c1e70","article-title":"Poor outcomes associated with neutropenia after kidney transplantation: analysis of United States Renal Data System","volume":"92","author":"Hurst","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2021.04.011_bib0017","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.transproceed.2008.02.048","article-title":"Leukopenia in kidney transplant patients with the association of valganciclovir and mycophenolate mofetil","volume":"40","author":"Brum","year":"2008","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2021.04.011_bib0018","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1111\/j.1600-6143.2009.02699.x","article-title":"Incidence, risk factors and clinical consequences of neutropenia following kidney transplantation: a retrospective study","volume":"9","author":"Zafrani","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2021.04.011_bib0019","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1046\/j.1523-1755.2000.00816.x","article-title":"Long-term survival in renal transplant recipients with graft function","volume":"57","author":"Ojo","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.transproceed.2021.04.011_bib0020","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1034\/j.1399-0012.2003.00026.x","article-title":"The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation","volume":"17","author":"Pelletier","year":"2003","journal-title":"Clin Transplant"},{"key":"10.1016\/j.transproceed.2021.04.011_bib0021","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1086\/528718","article-title":"Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation","volume":"46","author":"Arthurs","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.transproceed.2021.04.011_bib0022","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1097\/TP.0000000000002366","article-title":"A 2018 reference guide to the Banff classification of renal allograft pathology","volume":"102","author":"Roufosse","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2021.04.011_bib0023","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.transproceed.2020.01.036","article-title":"Evidence of interleukin-2-receptor-antibody induction in low-risk living donor kidney transplantation: a single-center pilot study","volume":"52","author":"Janigen","year":"2020","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2021.04.011_bib0024","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/tri.12485","article-title":"An update on ABO-incompatible kidney transplantation","volume":"28","author":"Zschiedrich","year":"2015","journal-title":"Transpl Int"},{"key":"10.1016\/j.transproceed.2021.04.011_bib0025","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1210\/jc.2015-1710","article-title":"Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline","volume":"101","author":"Bornstein","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.transproceed.2021.04.011_bib0026","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1705716","article-title":"Hydrocortisone plus fludrocortisone for adults with septic shock","volume":"378","author":"Annane","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transproceed.2021.04.011_bib0027","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/tri.12249","article-title":"Risk factors for impaired CD4+ T-cell reconstitution following rabbit antithymocyte globulin treatment in kidney transplantation","volume":"27","author":"Longuet","year":"2014","journal-title":"Transpl Int"},{"key":"10.1016\/j.transproceed.2021.04.011_bib0028","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1093\/ndt\/gfm468","article-title":"Is a standard fixed dose of mycophenolate mofetil ideal for all patients?","volume":"22","author":"Yau","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transproceed.2021.04.011_bib0029","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.trim.2014.06.001","article-title":"Late-onset neutropenia and acute rejection in ABO-incompatible kidney transplant recipients receiving rituximab and mycophenolate mofetil","volume":"31","author":"Kabei","year":"2014","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.transproceed.2021.04.011_bib0030","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.trim.2013.01.003","article-title":"Late-onset neutropenia (LON) after low-dose rituximab treatment in living related kidney transplantation\u2014single-center study","volume":"28","author":"Ishida","year":"2013","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.transproceed.2021.04.011_bib0031","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1034\/j.1399-3062.2000.020104.x","article-title":"Safety and efficacy of granulocyte colony-stimulating factor in kidney and liver transplant recipients","volume":"2","author":"Turgeon","year":"2000","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.transproceed.2021.04.011_bib0032","doi-asserted-by":"crossref","first-page":"e13541","DOI":"10.1111\/ctr.13541","article-title":"Single-center, real-world experience with granulocyte colony-stimulating factor for management of leukopenia following kidney transplantation","volume":"33","author":"Hamel","year":"2019","journal-title":"Clin Transplant"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004113452100258X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004113452100258X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:38:38Z","timestamp":1758577118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004113452100258X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S004113452100258X"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2021.04.011","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk Factors and Management of Leukopenia After Kidney Transplantation: A Single-Center Experience","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2021.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}